Medical News

RSS

454 Life Sciences launches new GS FLX+ System for high-throughput sequencing

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long sequencing reads up to 1,000 by in length.

28 Jun 2011

AMRI, Proteros ink new partnership

AMRI and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

28 Jun 2011

GM Hospital Group acquires Beijing hospital facility for HK$600,000,000

Golden Meditech Holdings Limited, is pleased to announce the acquisition of a hospital facility in Beijing's Haidian District for a total consideration of HK$600,000,000.

28 Jun 2011

Infection rate drops at Nebraska hospital after initiating new protocols

Nurses, occupational and physical therapists, case managers and education staff, all working together at a 300-bed Nebraska rehabilitation hospital, have successfully implemented a team approach to dramatically reduce infections from urinary catheters, the most prevalent type of infection acquired in healthcare settings.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

Federal Ministry of Health supports radionuclide production at Research Neutron Source

The German Federal Ministry of Health has awarded more than one million euros in research and development funding for the efficient production of an important cancer diagnostic agent at the research neutron source FRM II. In a 2009 feasibility study, the Technische Universitaet Muenchen demonstrated that due to the high neutron flux the neutron source in Garching can produce about half of the European demand of the radioisotope molybdenum-99.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).

28 Jun 2011

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.

28 Jun 2011

First Edition: June 28, 2011

Today's headlines include reports from the states about action on public employee benefit reforms and Planned Parenthood funding.

28 Jun 2011

Sentara, TeleHealth Services partner to reduce unplanned re-hospitalizations

TeleHealth Services, the nation's leading provider of healthcare-grade televisions and interactive patient education solutions, today announced a master agreement with Sentara Healthcare as part of the health system's strategy to advance the patient experience and quality of healthcare in its facilities.

28 Jun 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

RCSI researchers identify novel drug target for osteomyeltitis

New research from the Royal College of Surgeons in Ireland (RCSI) has identified a novel drug target for the treatment of infection in bone.

28 Jun 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

Merck, UPS extend logistics and distribution agreement

UPS and Merck, known as MSD outside the United States and Canada, today announced that the companies have significantly broadened their existing distribution and logistics agreement to include aspects of Merck's global supply chain around the world.

28 Jun 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

QIAGEN's common shares added to U.S. Russell indexes

QIAGEN N.V. today announced that its common shares were added to the U.S. large-cap Russell 1000 Index and the broad-market Russell 3000 Index.

From QIAGEN Manchester Limited 28 Jun 2011

Medical News

454 Life Sciences launches new GS FLX+ System for high-throughput sequencing

AMRI, Proteros ink new partnership

GM Hospital Group acquires Beijing hospital facility for HK$600,000,000

Infection rate drops at Nebraska hospital after initiating new protocols

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Nimbus Discovery closes $24 million Series A financing

Federal Ministry of Health supports radionuclide production at Research Neutron Source

Nine-year-old recovers with experimental heart pump

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

First Edition: June 28, 2011

Sentara, TeleHealth Services partner to reduce unplanned re-hospitalizations

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

RCSI researchers identify novel drug target for osteomyeltitis

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

Merck, UPS extend logistics and distribution agreement

EAS, ESC develop new European guidelines to manage dyslipidaemias

QIAGEN's common shares added to U.S. Russell indexes

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Latest News